The impact of dyslipidaemia on incidence of coronary heart disease in Finns and Swedes with different categories of glucose tolerance

Diabetes Research and Clinical Practice

Volumn 91, Issue 3, 2011, Pages 406-412

  Zhang, Lei ^a,b,c   Qiao, Qing ^a,b   Laatikainen, Tiina ^b   Söderberg, Stefan ^d,e   Jousilahti, Pekka ^b   Onat, Altan ^f,g   Nilsson, Peter ^h   Tuomilehto, Jaakko ^a,b,i  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c Qingdao Endocrine and Diabetes Institute   (China)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^f Turkish Society of Cardiology   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ SOUTH OSTROBOTHNIA CENTRAL HOSPITAL   (Finland)

Author keywords

Coronary heart disease; Diabetes; Impaired fasting glucose; Impaired glucose tolerance; Lipid

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FINLAND; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HAZARD RATIO; HUMAN; HYPERGLYCEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; FINLAND; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; SWEDEN;

EID: 79952364677     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.12.004     Document Type: Article

References (35)

1. Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med 1996, 28:341-345.
2. Syvanne M., Taskinen M.R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997, 350(Suppl. 1):SI20-23.
3. Zhang L., Qiao Q., Tuomilehto J., Hammar N., Alberti K.G., Eliasson M., et al. Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: the DECODE Study. Diabetes Res Clin Pract 2008, 82:364-377.
4. Pankow J.S., Kwan D.K., Duncan B.B., Schmidt M.I., Couper D.J., Golden S., et al. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007, 30:325-331.
5. Zhang L., Qiao Q., Tuomilehto J., Hammar N., Ruotolo G., Stehouwer C.D., et al. The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. Atherosclerosis 2009, 206:298-302.
6. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 1998, 317:371-375. The DECODE Study Group.
7. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621. The DECODE Study Group.
8. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003, 26:61-69. The DECODE Study Group.
9. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
10. Rimm A.A.H.A., Kalbfleisch J.H., Anderson A.J., Hoffmann R.G. Basic biostatistics in medicine and epidemiology 1980, Appleton-Century-Crofts, New York.
11. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86:19L-22L.
12. Mora S., Rifai N., Buring J.E., Ridker P.M. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118:993-1001.
13. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005, 112:3375-3383.
14. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322.
15. Onat A., Sari I., Yazici M., Can G., Hergenc G., Avci G.S. Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol 2006, 108:89-95.
16. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
17. Bos G., Dekker J.M., Nijpels G., de Vegt F., Diamant M., Stehouwer C.D., et al. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism-the Hoorn Study. Diabetologia 2003, 46:910-916.
18. Frost P.H., Davis B.R., Burlando A.J., Curb J.D., Guthrie G.P., Isaacsohn J.L., et al. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996, 94:2381-2388.
19. Festa A., D'Agostino R., Hanley A.J., Karter A.J., Saad M.F., Haffner S.M. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 2004, 53:1549-1555.
20. Nathan D.M., Davidson M.B., DeFronzo R.A., Heine R.J., Henry R.R., Pratley R., et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007, 30:753-759.
21. Meyer C., Pimenta W., Woerle H.J., Van Haeften T., Szoke E., Mitrakou A., et al. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006, 29:1909-1914.
22. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
23. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
24. Proctor S.D., Mamo J.C. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998, 28:497-503.
25. Alipour A., Elte J.W., van Zaanen H.C., Rietveld A.P., Cabezas M.C. Postprandial inflammation and endothelial dysfunction. Biochem Soc Trans 2007, 35:466-469.
26. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
27. Branchi A., Torri A., Berra C., Colombo E., Sommariva D. Changes in serum triglycerides and high-density lipoprotein concentration and composition after a low-fat mixed meal. Effects of gender and insulin resistance. Intern Emerg Med 2006, 1:287-295.
28. Rebolledo O.R., Actis Dato S.M. Postprandial hyperglycemia and hyperlipidemia-generated glycoxidative stress: its contribution to the pathogenesis of diabetes complications. Eur Rev Med Pharmacol Sci 2005, 9:191-208.
29. Freiberg J.J., Tybjaerg-Hansen A., Jensen J.S., Nordestgaard B.G. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008, 300:2142-2152.
30. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
31. Charlton-Menys V., Betteridge D.J., Colhoun H., Fuller J., France M., Hitman G.A., et al. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2009, 52:218-225.
32. Ingelsson E., Schaefer E.J., Contois J.H., McNamara J.R., Sullivan L., Keyes M.J., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776-785.
33. Karthikeyan G., Teo K.K., Islam S., McQueen M.J., Pais P., Wang X., et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol 2009, 53:244-253.
34. Sundvall J., Laatikainen T., Hakala S., Leiviska J., Alfthan G. Systematic error of serum triglyceride measurements during three decades and the effect of fasting on serum triglycerides in population studies. Clin Chim Acta 2008, 397:55-59.
35. WHO MONICA Project Principal Investigators The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988, 41:105-114.